Alumis Inc (ALMS) - Total Liabilities
Based on the latest financial reports, Alumis Inc (ALMS) has total liabilities worth $110.64 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Alumis Inc - Total Liabilities Trend (2022–2025)
This chart illustrates how Alumis Inc's total liabilities have evolved over time, based on quarterly financial data. See ALMS working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Alumis Inc Competitors by Total Liabilities
The table below lists competitors of Alumis Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanxi Securities Co Ltd
SHE:002500
|
China | CN¥71.93 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥6.46 Billion |
|
Ballarpur Industries Limited
NSE:BALLARPUR
|
India | Rs8.96 Billion |
|
ATS CORP
TO:ATS
|
Canada | CA$2.70 Billion |
|
Pan African Resources PLC
JSE:PAN
|
South Africa | ZAC469.72 Million |
|
HMS Networks AB (publ)
ST:HMS
|
Sweden | Skr3.04 Billion |
|
Genting Malaysia Bhd
KLSE:4715
|
Malaysia | RM19.44 Billion |
|
ATS CORP.
F:ATO0
|
Germany | €2.70 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Alumis Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ALMS stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alumis Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alumis Inc (2022–2025)
The table below shows the annual total liabilities of Alumis Inc from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $110.64 Million | +36.78% |
| 2024-12-31 | $80.89 Million | -81.14% |
| 2023-12-31 | $428.87 Million | +41.35% |
| 2022-12-31 | $303.41 Million | -- |
About Alumis Inc
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment o… Read more